Affiliation:
1. Department of Medicine, Smt. N.H.L. Municipal Medical College, Ahmedabad, Gujarat, India
2. Department of Medicine, G.C.S. Medical College, Ahmedabad, Gujarat, India
3. Department of Surgery, Smt. N.H.L. Municipal Medical College and SVPIMSR Hospital, Ahmedabad, Gujarat, India
4. Department of Pharmacology, Smt. N.H.L. Municipal Medical College, Ahmedabad, Gujarat, India
Abstract
Abstract
Background and Objective:
Tranexamic acid (TXA) has recently shown promising results in the treatment of melasma. The objective of this study was to generate statistical evidence on the efficacy of TXA with different routes.
Materials and Methods:
We searched studies in PubMed, Cochrane, ClinicalTrials.gov, and Scopus using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. A change in melasma area and severity index (MASI)/modified MASI score from the baseline at the end of 8 and 12 weeks was seen. Inverse variance method was used for continuous data to measure standard mean difference (SMD) at a 95% confidence interval (CI). RevMan version 5.4 was used for analysis, and statistical heterogeneity across studies was reported using I2 statistics. P < 0.05 was considered significant.
Results:
Totally, 28 randomized control trials were included. At 8 weeks, oral TXA showed a significant change in SMD of 1.61, 95% CI 0.44–2.79, P = 0.007; at 12 weeks, oral TXA showed SMD of 2.39, 95% CI 1.42–3.35, P < 0.00001 compared to adjuvant treatment. At 8 weeks, topical TXA did not show a significant change with SMD of -0.05, 95% CI -1.08–0.97, P = 0.92; at 12 weeks, topical TXA did not show a significant change with SMD of 0.66, 95% CI -0.10–1.42, P = 0.09 compared to adjuvant treatment. Similarly, for intradermal TXA at 8 weeks, results were not significant with SMD of 1.21, 95% CI -0.41–2.83, P = 0.14, and at 12 weeks, SMD was -0.55, 95% CI -2.27–1.18, P = 0.54 compared to adjuvant treatment.
Conclusion:
Tranexamic acid in an oral formulation can be used along with adjuvant treatment for the management of melasma. Data are still required for topical and intradermal routes. Owing to the fact that our included studies had a lot of heterogeneity, more research is needed along with addressing the adverse effects of tranexamic acid as well as its variation in different skin colors.